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Abstract
Background
There are two main types of strategies to identify target population for lung cancer screen-
ing: 1) strategies based on age and cumulative smoking criteria, 2) risk prediction models
allowing the calculation of an individual risk. The objective of this study was to compare dif-
ferent strategies to identify the proportion of the Spanish population at high risk of develop-
ing lung cancer, susceptible to be included in a lung cancer screening programme.
Methods
Cross-sectional study. We used the data of the Spanish National Interview Health Survey
(ENSE) of 2011–2012 (21,006 individuals) to estimate the proportion of participants at high
risk of developing lung cancer. This estimation was performed using the U.S. national lung
screening trial (NLST) criteria and a 6-year prediction model (PLCOm2012), both indepen-
dently and in combination.
Results
The prevalence of individuals at high risk of developing lung cancer according to the NLST
criteria was 4.9% (7.9% for men, 2.4% for women). Among the 1,034 subjects who met the
NLST criteria, 533 (427 men and 106 women) had a 6-year lung cancer risk2.0%. The
combination of these two selection strategies showed that 2.5% of the Spanish population
had a high risk of developing lung cancer. However, this selection process did not take into
account different groups of subjects <75 years old having an individual risk of lung cancer
2%, such as heavy smokers <55 years old who were long-time former smokers, and ever-
smokers having smoked <30 pack-years with other risk factors.
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Conclusions
Further research is needed to determine which selection strategy achieves a higher benefit/
harm ratio and to assess other prevention strategies for individuals with elevated risk for
lung cancer but who do not meet the screening eligibility criteria.
Introduction
Lung cancer is the most frequent of all cancers diagnosed in Europe and also the most com-
mon cause of cancer-related death [1], with an age-standardised 5-year survival of 13% for
adult patients with cancer diagnosed in 2000–2007 [2].
The implementation of a lung cancer screening programme at population level is contro-
versial as lung cancer screening has both benefits and harms [3,4] and previous trials have
shown inconsistent results. The national lung screening trial (NLST) in the United States
found that a lung cancer screening programme using annual computed tomography (CT) at
low dose for three years in high-risk ever-smokers may reduce lung cancer mortality by 20%
compared with conventional thoracic radiography [5]. In this trial, high-risk ever-smokers
were defined as ever-smokers aged 55–74 years old, having smoked30 pack-years and with
15 years since cessation for quitters. On the other hand, in Europe, the Danish lung cancer
screening trial (DLCST) compared low dose CT screening with no screening in a different
group of high-risk ever-smokers (50–70 years old, having smoked20 pack-years, age at ces-
sation >50 years old and quitting time <10 years for former smokers) and did not find any
significant differences in lung cancer mortality [6]. Another large European trial, the Dutch-
Belgian randomised lung cancer screening trial (NELSON), is actually ongoing. This trial aims
at comparing low dose CT screening with no screening in ever-smokers aged 50–75 years,
who smoked >15 cigarettes per day for >25 years or >10 cigarettes for >30 years, and were
still smoking or had quit10 years before recruitment [7].
Individuals at high risk of developing lung cancer may benefit from early detection through
screening based on low-dose CT. However, because low-dose CT screening has non-negligible
adverse effects (radiation exposure, false positives and overdiagnosis), identifying the most
appropriate target population is essential to maximise screening benefits and minimize adverse
effects. To help define the target population for lung cancer screening, some models allowing
the calculation of the individual risk of developing lung cancer have previously been published
[8]. These models take into account important risk factors, such personal and familiar disease
history and other relevant aspects of smoking, including smoking duration or intensity [9],
whereas the screening eligibility criteria used in the aforementioned clinical trials are only
based on age and the amount smoked in pack-years.
The objective of the present paper is to compare different strategies that could be used to
identify the proportion of the Spanish population at high risk of developing lung cancer, sus-
ceptible to be included in a lung cancer screening programme.
Methods
Although the analysis could have been performed without going through a research ethics
committee, as the data involved were de-identified and available for public use, we obtained
the approval of a Clinical Research Ethics Committee of the Bellvitge University Hospital (ref
PR249/16), as this analysis is part of a broader project entitled “Cost-effectiveness and budget
impact analysis of three preventive strategies in lung cancer".
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Study design and subjects
This is a cross-sectional analysis of the data from the Spanish National Health Survey (Encuesta
Nacional de Salud de España, ENSE), a cross-sectional survey on subjects15 years old, repre-
sentative of the non-institutionalized Spanish population.
This survey is conducted every five years and gathers health related information at national
level. Detailed information on the ENSE methodology is available on the website of the Span-
ish Ministry of Health (www.msssi.gob.es/en/estadEstudios/estadisticas/encuestaNacional/
ense.htm).
Briefly, survey participants were selected by means of probabilistic multistage sampling in
order to obtain representative data at regional and national level. The sampling method con-
sisted of a multistage cluster, where primary units were census tracts, secondary units were
households and the tertiary units (individuals) were selected from the description of household
members at the time of the interview. A sex and age-stratified sampling scheme have been
used for this survey.
The latest ENSE data available were collected in 2011–2012, they include information on
21,508 individuals, 21,006 having complete smoking history information. For the present anal-
ysis, no consent statement from participants was necessary, as all microdata are anonymised
and openly available on the aforementioned website.
Variables and analysis
The data of the ENSE survey were used to estimate the proportion of individuals at high risk of
developing lung cancer in the general population and among ever-smokers. High-risk partici-
pants were first defined using the NLST and NELSON trials criteria, based on age and cumula-
tive smoking exposure. The proportion of participants at high risk of developing lung cancer
obtained from the ENSE sample was then extrapolated into an absolute figure for the Spanish
population, using the latest available population census data of 2014 from the National Statis-
tics Institute (www.ine.es). Then, we estimated the 6-year individual risk of developing lung
cancer of current and former smokers from the ENSE survey using the model developed in the
context of the prostate, lung, colorectal and ovarian screening trial (PLCO trial) [10]. The vali-
dated 6-year prediction model for ever-smokers developed by Tammemägi et al. (PLCOm2012)
includes age, race/ethnicity, education, body mass index, personal history of cancer, family his-
tory of lung cancer, chronic obstructive pulmonary disease (COPD), smoking status, tobacco
consumption, smoking duration and time since quitting [11]. In the present analysis we did
not include the family history of lung cancer and ethnicity variables, as this information was
not available in the ENSE survey, and therefore assumed there was no risk due to family his-
tory of lung cancer and that all population was Caucasian. Instead of the 6-category education
variable of the PLCOm2012 model, we used a variable indicating the Spanish socioeconomic
status of the head of household [12]. This variable includes the following six categories: profes-
sions associated to postgraduate university degrees; professions associated to graduate univer-
sity degrees and qualified technicians; administrative employees and professionals, personal
service and self-employed workers, and supervisors of manual workers; skilled and semi-
skilled manual workers; unskilled workers. We described the distribution of the individual
6-year risk in quintiles of risk and also identified individuals with the following risk thresholds:
1.51% [11],2.00% [13] and5.00% [14].
Tammemägi et al. [11] found that1.51% level of risk, calculated with PLCOm2012, yielded
a mortality benefit for low-dose CT screening in the NLST and the number needed to screen
to prevent one lung cancer death would be reduced from 320 to 255. We also considered a 2%
threshold risk used in a study aimed to validate the performance of PLCOm2012 in predicting
Identifying high-risk individuals for lung cancer screening
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lung cancer outcomes in a cohort of Australian smokers. The study showed that it performed
better than the NLST [13]. Finally, we also considered the upper threshold (>5.00%) used in
the Liverpool Lung Project Risk Prediction Model for lung cancer incidence (LLPv2), in which
individuals whose 5-year predicted absolute risk was above 5.00% were designated as “high-
risk” group [14]. This threshold corresponded to the value for the 20% of predicted absolute
risk in the general Liverpool population. This risk algorithm has been used as the basis for risk
assessment in the UK Lung Cancer Screening Trial [14].
Finally, we described lung cancer risk factors [15] of NLST and ENSE participants at high
risk of developing lung cancer. For ENSE participants, three definitions were used to identify
high-risk participants: 1) individuals meeting NLST criteria, 2) individuals meeting NLST cri-
teria having a 6-year lung cancer risk of 2% or higher, and 3) individuals younger than 75
years having a 6-year lung cancer risk of 2% or higher, irrespective of NLST criteria.
Results
In the ENSE survey, the proportion of individuals at high risk of developing lung cancer was
6.6% (95% CI: 6.2%; 6.9%) according to the NELSON criteria and 4.9% (95% CI: 4.6%; 5.2%)
according to the NLST criteria (Table 1). The extrapolation of these percentages into absolute
figures shows that in Spain 2,653,744 individuals (1,862,034 men and 791,710 women) would
be considered at high risk of developing lung cancer if the NELSON criteria were applied. This
figure would went down to 2,003,483 individuals (1,523,120 men and 480,364 women) when
the NLST criteria were used.
Table 2 shows the distribution of the 6-year risk of developing lung cancer of ENSE partici-
pants who fulfilled the NLST criteria. This table shows that 72% of individuals who met the
NLST criteria exceeded the1.51% risk threshold. More than a half of current and former
smokers (56%) who had quit for less than 15 years, were aged 55–74 years old and had smoked
Table 1. Individuals (%) at high risk of developing lung cancer using the ENSE survey of 2011–2012 and extrapolation into absolute figures for the target popula-
tion at national level.
Population at risk in the ENSE sample Target population at national level
N NELSON criteria† NLST
criteria‡
Total population NELSON criteria† NLST criteria‡
% (95% CI) % (95% CI) n n N
General population
All 21,006 6.6 (6.2; 6.9) 4.9 (4.6; 5.2) 39,441,665 2,653,744 2,003,483
Men 9,648 9.7 (9.1; 10.3) 7.9 (7.4; 8.5) 19,234,370 1,862,034 1,523,120
Women 11,358 3.9 (3.6; 4.3) 2.4 (2.1; 2.7) 20,207,295 791,710 480,364
Ever-smoker population
All 9,496 14.5 (13.8; 15.2) 10.9 (10.3; 11.5) 18,122,937 2,653,744 2,003,483
Men 5,727 16.3 (15.4; 17.3) 13.3 (12.5; 14.2) 11,417,417 1,862,034 1,523,120
Women 3,769 11.8 (10.8; 12.8) 7.2 (6.3; 8.0) 6,705,520 791,710 480,364
 Target population using Spanish population census data of 2014 (www.ine.es).
 All population was used in the denominator for the computation of the prevalence.
 Ever-smoker population was used in the denominator for the computation of the prevalence.
† NELSON eligibility criteria: Age: 50–74 years. Smoking history: >15 cigarettes/day during >25 years; or >10 cigarettes/day during >30 years; if former smokers,
quitting time10 years. Trial registration number: ISRCTN63545820.
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30 pack-years, had a risk of developing lung cancer above 2%. Men showed a higher risk
than women; the median risk of developing lung cancer was 2.3% in men and 1.9% in women.
Survey participants who had a risk of developing lung cancer5% represent 15.3% of men
and 6.7% of women. When percentages were applied to the Spanish population, we estimated
that 2.5% of the Spanish population (1,039,860 individuals; 851,272 men and 188,587 women)
may have a risk of developing lung cancer2% (results not shown).
Table 3 shows smoking-related and other lung cancer risk factors among the populations of
the NLST trial and ENSE survey to which we applied the NLST criteria. The major differences
observed between these two populations were: a lower proportion of women in the Spanish
survey (26.1% vs 41.0% in the NLST trial) and a higher proportion of people smoking 20 or
more cigarettes per day (87.2% vs. 52.5% in the NLST trial). Table 3 also shows the characteris-
tics of the ENSE participants meeting the NLST criteria and having a risk of developing lung
cancer2%, calculated using the PLCOm2012 risk prediction model. This subpopulation at
higher risk of developing lung cancer included a higher proportion of subjects who were older,
had a diagnosis of COPD, and had smoked 40 or more pack-years.
Finally, Fig 1 describes ENSE participants with a high risk of developing lung cancer
(6-year risk2% according to the PLCOm2012 model) who would not be screened if the NLST
criteria were used to define the target population in the Spanish population. Among the 975
subjects having a 6-year risk2%, 342 did not meet the NLST criteria because they were 75
years old or older. The remaining group of 100 subjects who did not fulfil the NLST criteria
can be divided into three main groups. First, a group represents 6% of this subpopulation that
includes males <55 years old, often underweight, with extremely high cigarette consumption.
Second, a group representing 34% of the subpopulation that includes both men and women
who smoked less than 30 pack-years but had other risk factors, such a COPD diagnosis. Third,
a group representing 61% of the subpopulation, that includes older males, often overweight or
obese, who stopped smoking after having smoked for many years.
Regarding the lung cancer risk of never-smokers, from 9,630 never-smokers, only 17
(0.18%) showed2% risk of dying from lung cancer within 6 years.
Table 2. Distribution of the risk of developing lung cancer of Spanish ever-smokers who fulfilled the NLST criteria based on a 6-year risk model.
ENSE sample fulfilling NLST criteria
Overall
(n = 1,034) 
Men
(n = 764) 
Women (n = 270) 
Mean 2.91 3.12 2.26
Median 2.18 2.31 1.86
Quintile 1 0.55–1.30 0.55–1.36 0.56–1.21
Quintile 2 1.30–1.87 1.36–2.00 1.22–1.64
Quintile 3 1.87–2.64 2.00–2.84 1.65–2.16
Quintile 4 2.64–3.89 2.85–4.37 2.16–3.09
Quintile 5 3.90–21.98 4.38–21.98 3.09–9.14
Individuals with risks1.51%, n (%) 685 (72.0) 535 (74.9) 150 (63.0)
Individuals with risks2.00%, n (%) 533 (56.0) 427 (59.8) 106 (44.5)
Individuals with risks >5.00%, n (%) 125 (13.1) 109 (15.3) 16 (6.7)
 Based on the PLCOm2012 model, we included the following variables: age, socioeconomic status, body mass index, COPD, personal history of cancer, smoking status,
tobacco consumption, smoking duration and years of abstinence.
 Because of missing values for some of the variables used in the PLCOm2012 model, the risk of developing lung cancer could only be calculated for 952 (714 men and
238 women) ENSE participants fulfilling NLST criteria.
https://doi.org/10.1371/journal.pone.0195441.t002
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Table 3. Distribution of selected lung cancer risk factors among the NLST and ENSE populations at high risk of developing lung cancer.
NLST trial
(n = 53,158)
ENSE sample with NLST criteria
(n = 1,034)
ENSE sample with NLST criteria
and 6-year lung cancer risk2%
(n = 533)
N % (95% CI) N % (95% CI) N % (95% CI)
Sex
Men 31,365 59.0 (58.6; 59.4) 764 73.9 (71.2; 76.6) 427 80.1 (76.7; 83.5)
Women 21,793 41.0 (40.6; 41.4) 270 26.1 (23.4; 28.8) 106 19.9 (16.5; 23.3)
Age (years)
55–59 22,705 42.7 (42.3; 43.1) 366 35.4 (32.5; 38.3) 70 13.1 (10.3; 16.0)
60–64 16,288 30.6 (30.3; 31.0) 308 29.8 (27.0; 32.6) 167 31.3 (27.4; 35.3)
65–69 9,477 17.8 (17.5; 18.2) 228 22.1 (19.5; 24.6) 185 34.7 (30.7; 38.8)
70–74 4,681 8.8 (8.6; 9.0) 132 12.8 (10.7; 14.8) 111 20.8 (17.4; 24.3)
Body mass index
Underweight 458 0.9 (0.8; 0.9) 6 0.6 (0.1; 1.1) 6 1.1 (0.2; 2.0)
Normal 14,804 27.9 (27.6; 28.3) 280 29.0 (26.2; 31.9) 165 31.0 (27.0; 34.9)
Overweight 22.722 42.9 (42.5; 43.3) 456 47.3 (44.1; 50.4) 253 47.5 (43.2; 51.7)
Obese 14,985 28.3 (27.9; 28.7) 223 23.1 (20.4; 25.8) 109 20.5 (17.0; 23.9)
Smoking status
Current smoker 25,585 48.1 (47.7; 48.6) 474 45.8 (42.8; 48.9) 264 49.5 (45.3; 53.8)
Former smoker 27.573 51.9 (51.5; 52.3) 560 54.2 (51.1; 57.2) 269 50.5 (46.2; 54.7)
Cigarettes per day
10–19 25,261 47.5 (47.1; 47.9) 133 12.9 (10.8; 14.9) 67 12.6 (9.8; 15.4)
20–29 14,492 27.3 (26.9; 27.6) 493 47.7 (44.6; 50.7) 218 40.9 (36.7; 45.1)
30–39 9,625 18.1 (17.8; 18.4) 149 14.4 (12.3; 16.6) 82 15.4 (12.3; 18.4)
40–59 3,357 6.3 (6.1; 6.5) 192 18.6 (16.2; 20.9) 115 21.6 (18.1; 25.1)
60–79 349 0.7 (0.6; 0.7) 54 5.2 (3.9; 6.6) 39 7.3 (5.1; 9.5)
80 74 0.1 (0.1; 0.2) 13 1.3 (0.6; 1.9) 12 2.3 (1.0; 3.5)
Years of smoking
<30 5,709 10.7(10.5–11.0) 59 5.7 (4.3; 7.1) 11 2.1 (0.9; 3.3)
30–39 23,130 43.5 (43.1–43.9) 317 30.7 (27.8; 33.5) 81 15.2 (12.1; 18.2)
40–49 24,319† 45.7 (45.3–46.2) 494 47.8 (44.7; 50.8) 293 55.0 (50.7; 59.2)
50 164 15.9 (13.6; 18.1) 148 27.8 (24.0; 31.6)
Pack-years
30–39 13,662 25.7 (25.3; 26.1) 289 27.9 (25.2; 30.7) 71 13.3 (10.4; 16.2)
40–49 14,099 26.5 (26.2; 26.9) 274 26.5 (23.8; 29.2) 132 24.8 (21.1; 28.4)
50–59 7,358 13.8 (13.6; 14.1) 124 12.0 (10.0; 14.0) 80 15.0 (12.0; 18.0)
60 18,018 33.9 (33.5; 34.3) 347 33.6 (30.7; 36.4) 250 46.9 (42.7; 51.1)
Years of abstinence for former smokers
<5 11,301 41.4 (40.9; 42.0) 168 30.0 (26.2; 33.8) 97 36.1 (30.3; 41.8)
5–9 7,732 28.4 (27.8; 28.9) 172 30.7 (26.9; 34.5) 77 28.6 (23.2; 34.0)
10–14 8.239 30.2 (29.7; 30.8) 220 39.3 (35.2; 43.3) 95 35.3 (29.6; 41.0)
COPD diagnosis
No 48,938 92.3 (92.1; 92.5) 901 87.1 (85.1; 89.2) 433 81.2 (77.9; 84.6)
Yes 4,085 7.7 (7.5; 7.9) 133 12.9 (10.8; 14.9) 100 18.8 (15.4; 22.1)
 Based on the PLCO2012 model that includes: age, socioeconomic status, body mass index, COPD, personal history of cancer, smoking status, tobacco consumption,
smoking duration and years of abstinence. The NLST trial’s data was extracted from Katki et al. [15] and Kovalchik et al. [16].
† Information available for the population of the NLST trial:40 years smoked.
 The NLST trial included ever-smokers aged 55–74 years old, having smoked30 pack-years and15 years since cessation for quitters.
Note: Some variables do not sum up the total due to some missing values.
https://doi.org/10.1371/journal.pone.0195441.t003
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Discussion
The present study showed that an important part of the Spanish population may be at high
risk of developing lung cancer and could possibly benefit from screening. The application of
the inclusion criteria used by the NLST trial to a national health survey in Spain indicated that
4.9% of the survey participants were at high risk of developing lung cancer. The smoking char-
acteristics of the participants of the Spanish survey were significantly different from those of
the NLST trial. Both samples showed a similar distribution of the pack-years variable, but the
participants of the Spanish survey smoked more cigarettes per day than those of the NLST
trial. This finding stressed the importance of defining the lung cancer screening criteria that
would best fit the specific characteristics and needs of the Spanish population.
Previous studies have shown that individuals at high risk of developing lung cancer may
benefit from early detection based on low-dose CT screening [5]. Kovalchik et al. evaluated
whether low-dose CT screening benefits and harms varied according to the distribution of the
lung cancer risk; they found that low-dose CT screening prevented the greatest number of
deaths from lung cancer among participants who were estimated to be at the highest risk of
developing lung cancer [16]. Conversely, they also showed that low-dose CT screening pre-
vented very few deaths among those estimated to be at the lowest risk. Therefore, identifying
the most appropriate target population is essential to maximize screening benefits and mini-
mize adverse effects [17–19].
Fig 1. Distribution of ENSE participants with a 6-year lung cancer risk2% who did not meet the NLST criteria.  One individual was a former smoker for
more than 15 years and used to smoke<30 pack-years. Thus, the total sums up 101, not 100.
https://doi.org/10.1371/journal.pone.0195441.g001
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Several authors have previously tried to define strategies allowing the identification of target
populations for lung cancer screening. The two main types of strategies previously defined
were based on age and cumulative smoking exposure criteria on one hand (as in NELSON and
NLST trials) and on risk prediction models allowing the calculation of an individual risk on
the other hand [15,16]. Strategies using age and cumulative smoking exposure criteria are eas-
ier to implement; however, comparative studies have been shown they might be inferior to
strategies involving individual risk calculation [8,9,20]. For this reason, we decided to use
these two types of strategies both independently and in combination to identify which way of
selecting individuals for lung cancer screening would best fit our population.
The age and cumulative smoking exposure criteria used in the present study were those of
the large NLST trial, that showed a 20% decrease in mortality from lung cancer when low-dose
CT was compared with conventional thoracic radiography [5]. The risk prediction model used
was the PLCOm2012 model with a cut-off point of 2%. This threshold was chosen as a recent
study showed it performed better than the NLST, with superior sensitivity and specificity and
had higher sensitivity than the U.S. Preventive Services Task Force risk criteria [21] with no
loss in specificity [13].
However, we also calculated the proportion of individuals using a cut-off point of 1.51%
risk, but almost 3 out of 4 individuals who met NLST criteria exceeded this level of risk. On
the other hand, only 13.1% of individuals achieved the upper threshold (>5.0%). When
resources are limited and/or the intervention carried serious adverse effects, selecting a very
high-risk population is required to have a strong benefit-harm balance. The use of a conserva-
tive threshold is important, because previous studies have shown that low-dose CT screening
can lead to harm [22]. Also, the effect of restricting screening to a subpopulation of high-risk
individuals will reduce the cost of screening programmes at the expense of missing a propor-
tion of lung cancers in individuals below the cut-off. This high-risk strategy aims to help indi-
viduals with the greatest need of, and the potential to benefit from early detection. Such
stratification, mainly based on costs, available resources and public health impact of screening,
implies the difficult decision of where to place the cut-off [19].
When we applied the NLST criteria along with the PLCOm2012 lung cancer risk of2% to
the ENSE sample, we found out that 56.0% of the participants meeting the NLST criteria had a
6-year risk2%, representing 2.5% of the overall ENSE survey sample. According to these fig-
ures, we estimated that in Spain 1,039,860 individuals (851,272 men and 188,587 women) were
at high risk of developing lung cancer and could possibly get some benefit from being
screened. However, we also found that the combination of these two strategies would leave out
four groups of subjects of very different characteristics. The first group, which included indi-
viduals75 years old, is generally excluded from screening as mortality prevention due to
competing risks of death is likely to be less than for younger counterparts and may not fit a
curative treatment (surgery). In addition, adverse effects derived from the follow-up of lung
nodules with invasive diagnostic procedures are higher among the elderly.
The other three groups of individuals <75 years old with an individual risk of lung cancer
2% included: (i) heavy smokers <55 years old, (ii) long-time former smokers with a quitting
time >15 years, and (iii) ever-smokers having smoked <30 pack-years but having other risk
factors, such as obesity or COPD diagnosis. It is not clear whether these three groups should
be offered low-dose CT screening; however, their high risk of developing lung cancer should
be taken into account and they should be the target of strategies designed to reduce and/or
monitor their risk on a more individual basis [23]. We observed that different eligibility crite-
ria lead to selection of partially non-overlapping population. Further research is needed to
determine which selection strategy achieves a higher benefit/harm ratio and to assess other
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prevention strategies for individuals with elevated risk for lung cancer but who do not met the
screening eligibility criteria.
The approach used in the present analysis, that highlighted disparities between two differ-
ent ways of selecting the target population for lung cancer screening, corroborates the idea
that ‘one size may not fit all’ and that screening is likely to progressively become more closely
tailored to the actual level of risk of each individual [24].
Regarding lung cancer risk among never-smokers, we found that only 0.2% of them had
2% risk of developing lung cancer over a 6-year period. Ten Haaf and de Koning conducted
a microsimulation study to assess if never-smokers at elevated risk could be eligible for lung
cancer screening and if they may benefit from it. Their conclusion was that for most never-
smokers lung cancer screening is not beneficial [25].
Some limitations to this study deserve consideration. We could not include the family his-
tory of lung cancer or race/ethnicity as additional factors in the identification of ever-smokers
at highest risk of developing lung cancer, as this information was not gathered by the survey;
nevertheless, ethnicity is not such a relevant variable in Spain (high proportion of Caucasian:
93%-95%) [26], as it is in the United States.
On the other hand, this study is the first one that estimates the proportion of individuals at
high risk of developing lung cancer in Spain, that may benefit from lung cancer screening,
using both age and cumulative smoking exposure criteria and a risk model allowing individual
risk calculation.
In conclusion, the present study estimated that 2.5% of the Spanish population (1,039,860
individuals) is at high risk of developing lung cancer using the NLST criteria and the2% risk
threshold from PLCOm2012 combined, and could therefore be the target population for a lung
cancer screening programme. However, the selection strategy applied systematically may have
failed to identify specific subgroups of subjects, which could also possibly benefit from pro-
grammes designed to reduce and/or monitor their lung cancer risk. These findings showed
that lung cancer screening might benefit from a selection of the target population more closely
tailored to the level of risk of each individual.
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